Eloralintide is Eli Lilly's experimental amylin drug — a once-weekly injection that acts on the receptor for amylin, a hormone released by the pancreas alongside insulin, rather than on the GLP-1 receptor. Its one completed efficacy trial reported up to about 20% weight loss at 48 weeks, and Lilly has since registered five phase 3 trials. It is not approved anywhere.
This page is the trial record: what was tested, what the posted numbers show arm by arm, the side-effect counts, and what is running now. Everything was read from ClinicalTrials.gov and PubMed on 14 October 2026. For what an amylin agonist is in general, Peptide Lexicon's eloralintide entry gives the definition; this page does not repeat it.
The phase 2 trial, in one table
The study (NCT06230523) randomised 263 adults at 46 US centres with a BMI of 30 or more, or 27 or more with a weight-related condition, and without type 2 diabetes. Participants averaged 49 years and 109.1 kg; 78% were women. Each group injected once a week for 48 weeks. The results were published in The Lancet in December 2025 and posted to the registry on 24 June 2026.
| Arm | People | Weight change at 48 weeks | Reached ≥10% loss |
|---|---|---|---|
| Placebo | 53 | -0.4% | 12.9% |
| 1 mg | 28 | -9.4% | 53.3% |
| 3 mg | 24 | -12.4% | 60.5% |
| 6 mg | 28 | -17.6% | 76.6% |
| 9 mg | 54 | -20.1% | 82.3% |
| 6 mg → 9 mg | 24 | -19.9% | 91.1% |
| 3 → 6 → 9 mg | 52 | -16.5% | 79.2% |
Source: ClinicalTrials.gov posted results, least-squares means; the Lancet abstract reports the same arms rounded (-9% to -20%) under what it calls the efficacy estimand — the effect if people stay on treatment as assigned.
Two things the table shows that the headline does not. The placebo group lost almost nothing, so nearly the whole change is attributable to the drug in this trial. And the arms are small: four of the seven had 28 people or fewer, so the gap between, say, 6 mg and the 6-to-9 mg escalation is within what chance alone could produce.
Side effects: the starting dose mattered more than the final one
The Lancet abstract names nausea and fatigue as the most common adverse events. The registry's adverse-event table gives the counts, and glp1ledger converted them to percentages:
| Event | Placebo (53) | 6 mg from day one (28) | 9 mg (54) | 6 → 9 mg (24) | 3 → 6 → 9 mg (52) |
|---|---|---|---|---|---|
| Nausea | 13% | 64% | 33% | 54% | 25% |
| Vomiting | 0% | 25% | 11% | 17% | 2% |
| Fatigue | 11% | 29% | 43% | 46% | 21% |
| Constipation | 6% | 7% | 24% | 17% | 8% |
The pattern: people put straight onto 6 mg had the most nausea and vomiting, while the arm that stepped up from 3 mg through 6 mg to 9 mg had under a fifth of the vomiting rate of the fixed 9 mg arm and less than half its fatigue — at a cost of about 3.6 points of weight loss (-16.5% against -20.1%). Phase 2 trials often run fixed arms on purpose to map the dose range, so these are not the schedules a marketed product would use. Fatigue is the figure to watch: 43% on 9 mg against 11% on placebo is the largest drug-minus-placebo gap in the 9 mg column — larger than nausea (33% against 13%), and the phase 3 results will show whether it holds. What the approved GLP-1 labels record for tiredness is on our fatigue page.
The published abstract gives placebo nausea as 14%; the registry counts give 7 of 53, which is 13.2%. The difference is likely a denominator or rounding choice and does not change any comparison.
What is running now: the phase 3 programme
On 14 October 2026 ClinicalTrials.gov returned 18 studies that name eloralintide. Five are phase 3, all sponsored by Lilly and all listed as recruiting:
| Registry number | Who is enrolled | Planned size | Primary completion (estimated) |
|---|---|---|---|
| NCT07321886 | Obesity or overweight, no type 2 diabetes | 1,980 | March 2028 |
| NCT07282600 | Obesity or overweight with type 2 diabetes | 1,035 | January 2028 |
| NCT07353931 | Knee osteoarthritis pain with obesity or overweight | 900 | March 2028 |
| NCT07392190 | "Persistent obesity" while already on a weekly incretin | 900 | June 2028 |
| NCT07369011 | Obstructive sleep apnoea with obesity or overweight | 800 | March 2028 |
The total planned enrolment is about 5,600 people. The fourth trial is the most unusual: it enrols people who are already on a weekly incretin drug and still have obesity — the add-on question. Lilly has also completed a phase 1 study of eloralintide given with tirzepatide (NCT06916065, 188 people, completed January 2026) and is running phase 2 studies pairing it with macupatide, another of its experimental molecules (NCT07215559, NCT07589608). No results for the combinations had been posted when this page was written.
How it compares with the other amylin drugs
Eloralintide is one of several amylin-based drugs in development. Novo Nordisk's cagrilintide is furthest along, mainly as the semaglutide combination covered on our CagriSema page, and Novo's amycretin acts on both receptors in one molecule (amycretin). No trial has compared any of them head to head, and they were tested in different populations over different lengths of time, so a ranking from the published numbers would not be a fair comparison. The broader picture — that amylin drugs are being developed as an alternative or partner to GLP-1 drugs — is set out on how GLP-1 drugs work.
One point of overlap matters for anyone reading the muscle-loss debate. Amylin drugs, like GLP-1 drugs, reduce weight largely by reducing intake, and the phase 2 publication does not settle how much of the loss was lean tissue. The record on that question for the approved drugs is on our muscle loss page.
What is not established
- Long-term effect and safety. The longest completed trial is 48 weeks in 263 people. The phase 3 trials are the first large ones.
- Effect in type 2 diabetes. The phase 2 trial excluded it; NCT07282600 is the first large test.
- The dose that will be marketed. Phase 2 tested six regimens; the phase 3 registrations list the doses studied, not a final label.
- Price and availability. Nothing has been filed. Eloralintide is not sold legitimately anywhere, and anything offered under that name now is not Lilly's medicine.
Questions about whether an amylin drug, a GLP-1 drug or neither is appropriate belong with a clinician who knows the person's history.
Sources
- ClinicalTrials.gov, search "eloralintide" (intervention field), 18 records, and NCT06230523 posted results (results first posted 24 June 2026), clinicaltrials.gov, read 2026-10-14.
- Billings LK et al. "Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial." Lancet 2025;406:2631-2643, PubMed 41207310, doi 10.1016/S0140-6736(25)02155-5. Funded by Eli Lilly; seven authors are Lilly employees.
- Phase 3 records NCT07321886, NCT07282600, NCT07353931, NCT07392190, NCT07369011; combination studies NCT06916065, NCT07215559, NCT07589608, all at clinicaltrials.gov, read 2026-10-14.
- PubMed search "eloralintide": 10 records on 14 October 2026, including the phase 1 proof-of-concept report (Diabetes Obes Metab 2026, PubMed 41559929).